Your browser doesn't support javascript.
loading
The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease.
Pollock, Carol; Zuk, Anna; Anders, Hans-Joachim; Ganji, Mohammad Reza; Johnson, David W; Kasiske, Bertram; Langham, Robyn G; Pecoits-Filho, Roberto; Remuzzi, Giuseppe; Rossert, Jerome; Suzuki, Yusuke; Tanaka, Tetsuhiro; Walker, Robert; Yang, Chih-Wei; Bonventre, Joseph V.
Afiliación
  • Pollock C; Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
  • Zuk A; Akebia Research and Development Department, Akebia Therapeutics Inc., Cambridge, Massachusetts, USA.
  • Anders HJ; Division of Nephrology, Klinikum der Universität München (LMU), München, Germany.
  • Ganji MR; Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.
  • Johnson DW; Centre for Kidney Disease Research, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia.
  • Kasiske B; Translational Research Institute, Brisbane, Queensland, Australia.
  • Langham RG; Metro South and Ipswich Nephrology and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  • Pecoits-Filho R; Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
  • Remuzzi G; Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Rossert J; Monash Rural Health, Monash University, Clayton, Victoria, Australia.
  • Suzuki Y; Department of Internal Medicine, School of Medicine, Pontificia Universidade Catolica do Paraná, Curitiba, Brazil.
  • Tanaka T; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy.
  • Walker R; Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Yang CW; University of Milan, Milan, Italy.
  • Bonventre JV; Thrasos Therapeutics, Inc., Boston, Massachusetts, USA.
Kidney Int Suppl (2011) ; 7(2): 130-137, 2017 Oct.
Article en En | MEDLINE | ID: mdl-30675427
The focus of this article is to define goals and resulting action plans that can be collectively embraced by interested stakeholders to facilitate new therapeutic approaches to mitigate chronic kidney disease progression. The specific goals include identifying druggable targets, increasing the capacity for preclinical and early clinical development, broadening the availability of new therapeutic approaches, and increasing investment in the development of new therapies to limit chronic kidney disease. Key deliverables include the establishment of new regional, national, and global consortia; development of clinical trial networks; and creation of programs to support the temporary mutual movement of scientists between academia and the biotechnology and pharmaceutical sector. Other deliverables include cataloging and maintaining up-to-date records to collate progress in renal research and development, inventorying the capacity of research and clinical networks, and describing methods to ensure novel drug development.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Kidney Int Suppl (2011) Año: 2017 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Kidney Int Suppl (2011) Año: 2017 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos